Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

PRPH Price Correlated With Financials For ProPhase Labs

Free historical financial statements for ProPhase Labs Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 41 quarters since 2012. Compare with PRPH stock chart to see long term trends.

PRPH Stock Compared to Quarterly

PRPH Income Statement

Revenue, Net:47531000
Revenue Per Share:3.0693
Cost of Goods & Services Sold:18854000
Gross Profit:28677000
Selling, General & Admin Expense:7824000
Research & Development Expense:35000
Total Operating Expenses:12531000
Operating Income:16146000
Income Taxes:3416000
Net Income:12494000
Earnings Per Share, Basic:0.81
Shares Outstanding, Basic Avg:15485900

PRPH Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:1249000
Change in Accounts Receiveable:-1938000
Net Cash from Operations:20287000
Net Cash from Operations Per Share:1.31
Repurchases/Buybacks Common Stock:1150000
Cash Dividends Paid:4646000
Net Cash from Financing Activities:-7222000
Property, Plant & Equipment Purchases:1095000
Net Cash from Investing Activities:4084000
Net Change in Cash & Equivalents:17149000

PRPH Balance Sheet

Cash and Cash Equivalents:25807000
Short-Term Investments:3543000
Accounts Receivable, Net:36694000
Inventories:4680000
Total Current Assets:72555000
Property, Plant & Equipment, Net:6440000
Total Assets:99665000
Accounts Payable:8204000
Total Short-Term Liabilities:19770000
Total Liabilities:33220000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Barr Jason Michael   Director
721 sh at $6
$4,672
Buy
Barr Jason Michael   Director
750 sh at $6
$4,860
Buy
COMPANY PROFILE
Note
1 – Organization and Business

ProPhase
Labs, Inc. (“ProPhase”, “we”, “us”, “our” or the “Company”) is a diversified
company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. We provide traditional
CLIA molecular laboratory services, including SARS-CoV-2 (“COVID-19”) testing and seek to leverage our Clinical Laboratory
Improvement Amendments (“CLIA”) accredited laboratory services to provide whole genome sequencing and research direct to
consumers, while building a genomics data base to be used for further research. In addition, we have deep experience with over-the-
counter (“OTC”) consumer healthcare products and dietary supplements. We currently conduct our operations through two operating
segments: diagnostic services and consumer products. Until late Fiscal 2020, we were engaged primarily in the research, development,
manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. However,
commencing in December 2020, we also began offering COVID-19 and other Respiratory Pathogen Panel (RPP) molecular tests through our new
diagnostic services business, and in August 2021 we began offering personal genomics products and services.

Our
wholly owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers
a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain
reaction (“PCR”) testing for COVID-19. Critical to COVID-19 testing, we provide fast turnaround times for results. We also
offer rapid antigen and antibody/immunity testing for COVID-19. On October 23, 2020, we acquired Confucius Plaza Medical Laboratory Corp.
(“CPM”), which included a non-operating but certified 4,000 square foot CLIA accredited laboratory located
in Old Bridge, New Jersey (see Note 3, Business Acquisitions). In December 2020, we expanded our diagnostic service business with the
build out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in January
2021.

On
August 10, 2021, we acquired Nebula Genomics, Inc. (“Nebula”), a privately owned personal genomics company (“Nebula”),
through our new wholly owned subsidiary, ProPhase Precision Medicine, Inc. (“ProPhase Precision”). See Note 3, Business Acquisitions.
ProPhase Precision focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes
and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict
disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

Our
wholly owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label
developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.

Data imported from ProPhase Labs Inc. SEC filings. Check original filings before making any investment decision.